» Articles » PMID: 35955904

Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes ( and )

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 Aug 12
PMID 35955904
Authors
Affiliations
Soon will be listed here.
Abstract

The proper regulation of nucleotide pools is essential for all types of cellular functions and depends on de novo nucleotide biosynthesis, salvage, and degradation pathways. Despite the apparent essentiality of these processes, a significant number of rare diseases associated with mutations in genes encoding various enzymes of these pathways have been already identified, and others are likely yet to come. However, knowledge on genetic alterations impacting on nucleoside and nucleobase transporters is still limited. At this moment three gene-encoding nucleoside and nucleobase transporter proteins have been reported to be mutated in humans, , , and , impacting on the expression and function of ENT1, ENT3, and CNT1, respectively. ENT1 alterations determine Augustine-null blood type and cause ectopic calcification during aging. ENT3 deficiency translates into various clinical manifestations and syndromes, altogether listed in the OMIM catalog as histiocytosis-lymphoadenopathy plus syndrome (OMIM#602782). CNT1 deficiency causes uridine-cytidineuria (URCTU) (OMIM#618477), a unique type of pyrimidineuria with an as yet not well-known clinical impact. Increasing knowledge on the physiological, molecular and structural features of these transporter proteins is helping us to better understand the biological basis behind the biochemical and clinical manifestations caused by these deficiencies. Moreover, they also support the view that some metabolic compensation might occur in these disturbances, because they do not seem to significantly impact nucleotide homeostasis, but rather other biological events associated with particular subtypes of transporter proteins.

Citing Articles

Lysosomal dysfunction and overload of nucleosides in thymidine phosphorylase deficiency of MNGIE.

Du J, Liu F, Liu X, Zhao D, Wang D, Sun H J Transl Med. 2024; 22(1):449.

PMID: 38741129 PMC: 11089807. DOI: 10.1186/s12967-024-05275-8.


Adenine-induced animal model of chronic kidney disease: current applications and future perspectives.

Yang Q, Su S, Luo N, Cao G Ren Fail. 2024; 46(1):2336128.

PMID: 38575340 PMC: 10997364. DOI: 10.1080/0886022X.2024.2336128.


How Cryo-EM Has Expanded Our Understanding of Membrane Transporters.

Baril S, Gose T, Schuetz J Drug Metab Dispos. 2023; 51(8):904-922.

PMID: 37438132 PMC: 10353158. DOI: 10.1124/dmd.122.001004.


Overcoming Biological Barriers: Importance of Membrane Transporters in Homeostasis, Disease and Disease Treatment.

Ciarimboli G Int J Mol Sci. 2023; 24(8).

PMID: 37108379 PMC: 10138362. DOI: 10.3390/ijms24087212.

References
1.
Govindarajan R, Leung G, Zhou M, Tse C, Wang J, Unadkat J . Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009; 296(4):G910-22. PMC: 2670673. DOI: 10.1152/ajpgi.90672.2008. View

2.
Kang N, Jun A, Bhutia Y, Kannan N, Unadkat J, Govindarajan R . Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem. 2010; 285(36):28343-52. PMC: 2934698. DOI: 10.1074/jbc.M110.109199. View

3.
Rafiq N, Hussain K, Brogan P . Tocilizumab for the Treatment of SLC29A3 Mutation Positive PHID Syndrome. Pediatrics. 2017; 140(5). DOI: 10.1542/peds.2016-3148. View

4.
Ochs H, Yount J, GIBLETT E, Chen S, Scott C, Wedgwood R . Adenosine-deaminase deficiency and severe combined immunodeficiency syndrome. Lancet. 1973; 1(7816):1393-4. DOI: 10.1016/s0140-6736(73)91725-x. View

5.
Altaweraqi R, Yao S, Smith K, Cass C, Young J . HPLC reveals novel features of nucleoside and nucleobase homeostasis, nucleoside metabolism and nucleoside transport. Biochim Biophys Acta Biomembr. 2020; 1862(7):183247. DOI: 10.1016/j.bbamem.2020.183247. View